David Leslie Szekeres - Jul 13, 2022 Form 4 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)

Role
EVP, Chief Operating Officer
Signature
/s/ Lisa Peraza Attorney-in-fact for David Szekeres
Stock symbol
HRTX
Transactions as of
Jul 13, 2022
Transactions value $
-$274
Form type
4
Date filed
7/15/2022, 04:58 PM
Previous filing
Apr 15, 2022
Next filing
Jul 27, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HRTX Common Stock Other $5.78K +1.51K +12.99% $3.84 13.1K Apr 29, 2022 Direct F1
transaction HRTX Common Stock Options Exercise +1.25K +9.55% 14.3K Jul 13, 2022 Direct F2
transaction HRTX Common Stock Options Exercise +4.56K +31.83% 18.9K Jul 13, 2022 Direct F2
transaction HRTX Common Stock Tax liability -$6.06K -2.01K -10.64% $3.01 16.9K Jul 13, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HRTX Restricted Stock Units Options Exercise $0 -1.25K -10% $0.00 11.3K Jul 13, 2022 Common Stock 1.25K Direct F2, F4
transaction HRTX Restricted Stock Units Options Exercise $0 -4.56K -9.88% $0.00 41.6K Jul 13, 2022 Common Stock 4.56K Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 29, 2022.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 Represents the withholding by the Company of certain of the vested shares of restricted stock to satisfy the minimum statutory tax obligations applicable to such transactions.
F4 The restricted stock units vest in 16 equal quarterly installments beginning one quarter after the date of grant (10/13/2020).
F5 The restricted stock units vest quarterly with 33% of the shares vesting during the first year, 33% of the shares vesting during the second year, 22% of the shares vesting during the third year and the remaining 12% of the shares vesting during the fourth year, such that all shares will be fully vested on the four year anniversary of the date of grant (10/13/2021).